A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 7637 participants.
Also called NCT01959529
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 7,637 participants
- Sponsor
- Registry
-
NCT01959529 -
2013-002371-17
-
- Other papers using this trial's data
- Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)
- DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality
- Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)
- Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1
- Developing, Planning and Conducting an Interim Analysis: Lessons From the DEVOTE Cardiovascular Outcomes Trial (Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events)
- Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
- Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14
- Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE
- Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10)
- Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12)
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Algeria, Argentina, Brazil, Canada, Croatia, Greece, India, Italy, Japan, Malaysia, Mexico, Poland, Romania, Russia, South Africa, South Korea, Spain, Thailand, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01959529. Randomized; double masking; primary purpose treatment. Start 2013-10-29 (actual); primary completion 2016-10-16 (actual). Results posted on 2017-11-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events
- Acronym
- DEVOTE
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec
- Intervention (Drug)
- insulin glargine
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01959529- Content hash
76b90c09baf5042295b7dd4803e4c5fef8832720f413731e19c05886be5525d2